Home » Biotechnology » Tuberculosis Treatment Market

Tuberculosis Treatment Market By Drug Class (First Line Treatment, Second Line Treatment) – Growth, Share, Opportunities & Competitive Analysis, 2017 – 2025

Summary
Table Of Content

Market Insights

This report on the global tuberculosis treatment market studies various drug classes. According to the World Health Organization (WHO), approximately 49 million lives were saved from 2000-2015 through effective diagnosis and treatment. Its End T.B. Strategy aims to eradicate the global T.B. epidemic with a 95% reduction in T.B. deaths, cut new cases by 90% from 2015 to 2035, and ensure that patients are not burdened with huge expenses incurred due to T.B. The drivers of the tuberculosis treatment market are the rising prevalence of T.B. and MDR-TB, increasing public awareness regarding tuberculosis, and immediate enrollment of patients on the treatment regimen. The promising pipeline to overcome drug-induced resistance consists of bedaquiline, OPC-67683, PA-824, OFLOTUB, etc.

For the purpose of this study, the various drug classes of tuberculosis treatment studied include the first line of treatment, which is segmented as isoniazid, ethambutol, pyrazinamide, and rifampin. Ethionamide, Cycloserine, Para-amino-Salicylic Acid, and Kanamycin comprise the second line of treatment. The global tuberculosis treatment market is segmented geographically into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa markets. Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints, and opportunities) to have a good understanding of the current and anticipated trends in the global tuberculosis treatment market. Competition assessment tools such as market attractiveness assessment and competitive landscape analysis by key players are also demonstrated in the study. Furthermore, this report concludes with a profile of key market players currently enjoying prominent positions in the global tuberculosis treatment market. The key players profiled in this report are Bayer Healthcare, Eli Lilly & Co., Labatec Pharma SA, Macleods Pharmaceuticals Pvt. Ltd., Mylan N.V., Novartis AG, Otsuka Novel Products GmbH, Patheon, Inc., Pfizer, Inc., and Sanofi S.A.

Based on drug class, the global tuberculosis treatment market is categorized into:

First-line treatment

Cytochrome P-450 Inhibitor (Isoniazid)
Mycolic acid inhibitor (Ethambutol)
FAS I inhibitor (pyrazinamide)
RNA polymerase inhibitor (Rifampin)

Second-line treatment

Mycolic acid inhibitor (Ethionamide)
Peptidoglycan inhibitor (Cycloserine)
Folic acid inhibitor (para-aminosalicylic acid)
30S ribosomal inhibitor (kanamycin)

The United Nations adopted the Sustainable Development Goals (SDGs) in 2015, with eradicating tuberculosis as one of its major goals; similarly, the World Health Organization claims that its tuberculosis strategy will achieve a 90% reduction in tuberculosis deaths and an 80% reduction in T.B. incidence rate by 2030. The growing public awareness of tuberculosis and its treatment regimen, as well as its low cost, is driving the growth of the tuberculosis drug class segment. In 2016, first-line treatment held the largest market due to the increasing number of new cases of T.B., early T.B. screening resulting in a large turnout of patients on first-line treatment, and government initiatives such as DOTS at the primary health centers to bring under its ambit patients with unmet medical needs.

Second-line treatment will register faster growth throughout the forecast period of 2017–2025 due to factors such as the rising prevalence of MDR-TB (according to the World Health Organization, in 2015, there were 480,000 new reported cases), lack of patient compliance with the prescribed first-line treatment dosage regimen, and rising incidences of hospital-acquired infections. Overall, the tuberculosis drug market is highly competitive, with multiple players like Novartis AG, Bayer Healthcare, Labatec Pharma S.A., Mylan N.V., Otsuka Novel Products GmbH, etc., specializing in their respective fields. Consolidation activities are being increasingly witnessed on the competitive front with a view to increasing the technological advancement in drug formulation regarding the pharmacodynamics and pharmacokinetic aspects for better patient compliance and low cost.

For the purpose of this study, the global tuberculosis treatment market is categorized into:

North America
- US.
- Canada
Europe
- Germany
- France
- UK.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa

North America will be the fastest-growing market for tuberculosis treatment throughout the forecast period of 2017–2025. According to the Centers for Disease Control and Prevention, 9,421 TB cases were reported in 2014, i.e., a rate of 2.96 cases per 100,000 persons. The market growth is mainly attributed to the rising prevalence of tuberculosis, an evolving reimbursement scenario, and a developed healthcare infrastructure. According to the World Health Organization (WHO), in 2015, 32,000 patient deaths were reported in Europe. The growth of the tuberculosis treatment market is attributed to the prevalence of MDR-TB in eastern European countries and supportive regulatory approval for the tuberculosis treatment market. In the base year 2016, Asia Pacific was observed as the leading market for tuberculosis treatment due to factors such as the rising prevalence of tuberculosis, according to the World Health Organization.

South East Asia had 4.8 million prevalent cases and 450,000 deaths in 2012, creating a competitive market due to manufacturers involved in the production of tuberculosis treatment drugs, increasing disposable income in these regions, and government and non-government initiatives such as DOTS to mitigate tuberculosis. However, factors such as developing health infrastructure and increasing awareness about tuberculosis treatment are going to fuel the rapid growth of the tuberculosis treatment market in Latin America, the Middle East, and Africa in the near future.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Tuberculosis Treatment Market Portraiture
2.2 Global Tuberculosis Treatment Market, by Drug Class, 2016 (US$ Mn)
2.3 Global Tuberculosis Treatment Market, by Geography, 2016 (Value %)

Chapter 3 Global Tuberculosis Treatment Market: Market Dynamics and Future Outlook
3.1 Overview
3.2 Market Drivers
3.2.1 Rising prevalence of tuberculosis and MDR-TB
3.2.2 For a full, detailed list, browse our report
3.3 Market Restraints
3.3.1 Technological advancement in the development of tuberculosis vaccines market will hinder the tuberculosis drug market
3.3.2 For a full, detailed list, browse our report
3.4 Market Opportunities
3.4.1 Promising pipeline to overcome the drug induced resistance
3.4.2 For a full, detailed list, browse our report
3.5 Attractive Investment Proposition
3.6 Market Competition Assessment: Tuberculosis Treatment Market, by Key Players

Chapter 4 Global Tuberculosis Treatment Market, by Drug Class, 2015-2025 (US$ Mn)
4.1 Introduction
4.2 First line Treatment
4.2.1 Cytochrome P450 inhibitor (Isoniazid)
4.2.2 Mycolic acid inhibitor (Ethambutol)
4.2.3 FAS I inhibitor (Pyrazinamide)
4.2.4 RNA polymerase inhibitor (Rifampin)
4.3 Second Line Treatment
4.3.1 Mycolic acid inhibitor (Ethionamide)
4.3.2 Peptidoglycans inhibitor (Cycloserine)
4.3.3 Folic acid inhibitor (Para-amino salicylic acid)
4.3.4 30S ribosome inhibitor (Kanamycin)

Chapter 5 Global Tuberculosis Treatment Market, by Geography, 2015-2025 (US$ Mn)
5.1 Preface
5.2 North America
5.2.1 North America Tuberculosis Treatment Market,by Drug Class, 2015-2025 (US$ Mn)
5.2.2 North America Tuberculosis Treatment Market,by Country, 2015-2025 (US$ Mn)
5.2.2.1 U.S.
5.2.2. 2 Canada
5.3 Europe
5.3.1 Europe Tuberculosis Treatment Market,by Drug Class, 2015-2025 (US$ Mn)
5.3.2 Europe Tuberculosis Treatment Market,by Country, 2015-2025 (US$ Mn)
5.3.2.1 U.K.
5.3.2.2 Germany
5.3.2.3 Rest of Europe
5.4 Asia Pacific
5.4.1 Asia Pacific Tuberculosis Treatment Market, by Drug Class, 2015-2025 (US$ Mn)
5.4.2 Asia Pacific Tuberculosis Treatment Market,by Country, 2015-2025 (US$ Mn)
5.4.2.1 China
5.4.2.2 Japan
5.4.2.3 Rest of Asia Pacific
5.5 Latin America
5.5.1 Latin America Tuberculosis Treatment Market,by Drug Class, 2015-2025 (US$ Mn)
5.5.2 Latin America Tuberculosis Treatment Market,by Country, 2015-2025 (US$ Mn)
5.5.2.1 Brazil
5.5.2.2 Mexico
5.5.2.3 Rest of Latin America
5.6 Middle East and Africa
5.6.1 Middle East and Africa Tuberculosis Treatment Market,by Drug Class, 2015-2025 (US$ Mn)
5.6.2 Middle East and Africa Tuberculosis Treatment Market,by Country, 2015-2025 (US$ Mn)
5.6.2.1 GCC
5.6.2.2 Rest of Middle East and Africa

Chapter 6 Company Profiles
6.1 Bayer Healthcare
6.2 Eli Lilly & Co.
6.3 Labatec Pharma SA
6.4 Macleods Pharmaceuticals Pvt Ltd.
6.5 Mylan N.V.
6.6 Novatis AG
6.7 Otsuka Novel Products GmbH
6.8 Patheon, Inc.
6.9 Pfizer, Inc.
6.10 Sanofi S.A.

List of Figures

FIG. 1 Global Tuberculosis Treatment Market: Research Methodology
FIG. 2 Global Tuberculosis Treatment Market, by Drug Class, 2016 (US$ Mn)
FIG. 3 Global Tuberculosis Treatment Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography, 2016
FIG. 5 Market Positioning of Key Tuberculosis Treatment Vendors, 2016
FIG. 6 Isoniazid Drug Class Market, 2015 – 2025 (US$ Mn)
FIG. 7 Ethambutol Drug Class Market, 2015 – 2025 (US$ Mn)
FIG. 8 Pyrazinamide Drug Class Market, 2015 – 2025 (US$ Mn)
FIG. 9 Rifampin Drug Class Market, 2015 – 2025 (US$ Mn)
FIG. 10 Ethionamide Drug Class Market, 2015 – 2025 (US$ Mn)
FIG. 11 Cycloserine Drug Class Market, 2015 – 2025 (US$ Mn)
FIG. 12 Para-aminosalicylic acid Drug Class Market, 2015 – 2025 (US$ Mn)
FIG. 13 Kanamycin Drug Class Market, 2015 – 2025 (US$ Mn)
FIG. 14 U.S. Tuberculosis Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 15 Canada Tuberculosis Treatment Market , 2015– 2025 (US$ Mn)
FIG. 16 U.K. Tuberculosis Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 17 Germany Tuberculosis Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 18 Rest of Europe Tuberculosis Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 19 China Tuberculosis Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 20 Japan Tuberculosis Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 21 Rest of Asia Pacific Tuberculosis Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 22 Brazil Tuberculosis Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 23 Mexico Tuberculosis Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 24 Rest of Latin America Tuberculosis Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 25 GCC Tuberculosis Treatment Market , 2015 – 2025 (US$ Mn)
FIG. 26 Rest of Middle East and Africa Tuberculosis Treatment Market , 2015 – 2025 (US$ Mn)

List of Tables

TABLE 1 Global Tuberculosis Treatment Market, By Drug Class, 2015-2025 (US$ Mn)
TABLE 2 Global Tuberculosis Treatment Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 3 North America Tuberculosis Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 4 North America Tuberculosis Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 5 Europe Tuberculosis Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 6 Europe Tuberculosis Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 7 Asia Pacific Tuberculosis Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 8 Asia Pacific Tuberculosis Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 9 Latin America Tuberculosis Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 10 Latin America Tuberculosis Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 11 Middle East and Africa Tuberculosis Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 12 Middle East and Africa Tuberculosis Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 13 Bayer Healthcare : Company Snapshot (Business Description, Financial Information, Product Portfolio and News Coverage)
TABLE 14 Eli Lilly & Co. : Company Snapshot (Business Description, Financial Information, Product Portfolio and News Coverage)
TABLE 15 Labatec Pharma SA : Company Snapshot (Business Description, Financial Information, Product Portfolio and News Coverage)
TABLE 16 Macleods Pharmaceuticals Pvt. Ltd. : Company Snapshot (Business Description, Financial Information, Product Portfolio and News Coverage)
TABLE 17 Mylan N.V. : Company Snapshot (Business Description, Financial Information, Product Portfolio and News Coverage)
TABLE 18 Novartis AG : Company Snapshot (Business Description, Financial Information, Product Portfolio and News Coverage)
TABLE 19 Otsuka Novel Products GmbH : Company Snapshot (Business Description, Financial Information, Product Portfolio and News Coverage)
TABLE 20 Patheon, Inc. : Company Snapshot (Business Description, Financial Information, Product Portfolio and News Coverage)
TABLE 21 Pfizer, Inc. : Company Snapshot (Business Description, Financial Information, Product Portfolio and News Coverage)
TABLE 22 Sanofi S.A. : Company Snapshot (Business Description, Financial Information, Product Portfolio and News Coverage)

Frequently Asked Questions:

What is the size of Tuberculosis Treatment Market?

The market for Tuberculosis Treatment Market is expected to reach US$ 1,306.6 Mn By 2025.

What is the Tuberculosis Treatment Market CAGR?

The Tuberculosis Treatment Market is expected to see significant CAGR growth over the coming years, at 4.9%.

What is the Forecast period considered for Tuberculosis Treatment Market?

The report is forecasted from 2017-2025.

What is the base year considered for Tuberculosis Treatment Market?

The base year of this report is 2016.

Who are the major players in this market?

Eli Lilly & Co., Labatec Pharma SA, Macleods Pharmaceuticals Pvt. Ltd., Mylan N.V., Novartis AG, Otsuka Novel Products GmbH, Patheon, Inc., Pfizer, Inc., and Sanofi S.A. are some of the major players in the global market.

Purchase Options

Single User

$3699

Multi User

$4699

Custom Report

$6699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –